新闻动态

新闻动态

讲座/研讨会

Last call to join us in Lisbon!

We look forward to hosting you at the upcoming 22nd Planova™ Workshop in Lisbon where professionals from around the world will gather to share their expertise on topics such as virus filtration fundamentals, process development, robust manufacturing and new trends.

Confirmed chairs, speakers and tentative presentation titles are shown below.

Chairs

Thomas R. Kreil, Ph.D.
Vice President, Global Pathogen Safety, Associate Professor of Virology, Takeda

Salvador Grancha, Ph.D.
R&D Vice President, Biologics Industrial Group, Grifols

Uwe Gottschalk, Ph.D.
Chief Scientific Officer, Pharma/Biotech, Lonza

Nathan J. Roth, Ph.D.
Executive Director, Global Pathogen Safety, R&D, CSL Behring

Speakers and Presentations

Fundamental Knowledge

Challenges in Virus Filtration for Pioneering Biologics Safety and Manufacturing Efficiency: History and Advances
Tomoko Hongo-Hirasaki, Ph.D., Lead Expert, Scientific Affairs, Global Marketing, Bioprocess Division, Asahi Kasei Medical

Regulatory Developments in Viral Safety
Johannes Blümel, Ph.D., Head of Virus Safety Section, Department of Virology, Paul-Ehrlich-Institut

Strategies for Controlling Virus Risk in Upstream Processes
Andy Bailey, Ph.D., CEO & Operations Director, ViruSure

Quantitative Visualization of Virus Behavior in Planova™ Membrane Filters Using Optical Microscope
Takayuki Nishizaka, Ph.D., Professor, Department of Physics, Gakushuin University

Implementation of Virus Removing Filtration - Challenges to Overcome
Ingrid M.M. Prins-de Nijs, Project Leader, Product Development, Sanquin Plasma Products

Hepatitis E Virus Filtration

A Non-Enveloped Virus with a Lipid Envelope: Antibody Enhanced Hepatitis E Virus Nanofiltration During the Manufacture of Human Immunoglobulin
Andreas Wieser, DI (FH), Senior Laboratory Associate, Global Pathogen Safety, Takeda

Impact of Matrix Conditions on Small Virus Challenges to 35-nm Filtration: Case Study of Hepatitis A and E Viruses in the Context of a Virus Safety Evaluation of an Immune Globulin from Human Plasma
Francisco Belda, Ph.D., Pathogen Safety Coordination Section Manager, Pathogen Safety, R&D Global Product Safety, Bioscience Industrial Group, Grifols

Practical Approach to Evaluating the Removal of Hepatitis E Virus, a Membrane-Associated Non-Enveloped Virus by Nanofiltration Membrane
Kaoru Sakai, Ph.D., General Manager, Central Research Laboratory, Japan Blood Products Organization

Robust Manufacturing

Next Generation Processes: Challenges and Considerations for Robust Validation of Viral Filtration Applications
James Eagles, MS&T Purification Scientist, Manufacturing Science & Technology Group, Bristol-Myers Squibb

Adoption of Planova™ BioEX to Platform Purification Process
John K. Zehmer, Ph.D., Scientist III, Purification Sciences, MacroGenics

Robust Virus Removal in Boehringer Ingelheim's Downstream Platform Processes
Simon Reitz, Ph.D., Associate Director, Protein Science, BioProcess + Analytical Dev.,
Boehringer Ingelheim Pharma

New Trends and Virus Filtration Fundamentals

Aggregate Clearance in the Production of Viral Vaccines
Leila Dias, Ph.D., Senior DSP Scientist, Process Development, Viral Vaccines, Intravacc

Virus Reduction for Large Proteins: Nanofiltration and UV-C Irradiation, a Complementary Approach
Marcel Asper, Ph.D., Director Virus Laboratory - Pathogen Safety, Biotest

Process Development and Impact of Critical Process Parameters on Virus Filtration
Walter Elffrink, B.Sc., Senior Researcher, Downstream processing, Synthon Biopharmaceuticals

Choice of Parvovirus Model (CPV, MVM, PPV) Influences the Interpretation of the Effectiveness of Virus Filtration Steps
Thomas Nowak, Ph.D., Senior Manager, Global Pathogen Safety, CSL Behring

From "Batch Mode" to "Continuous" Bioprocessing: How the Virus Filter Fits In
Daniel Strauss, Ph.D., Principal Scientist, Science and Technology, Asahi Kasei Bioprocess America

We would be honored to host you in the beautiful city of Lisbon. Additional information is available on The 22nd Planova™ Workshop Page.